Clozapine treatment and risk of COVID-19 infection: retrospective cohort study
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Clozapine, an antipsychotic with unique efficacy in treatment-resistant psychosis, is associated with increased susceptibility to infection, including pneumonia.
Aims
To investigate associations between clozapine treatment and increased risk of COVID-19 infection in patients with schizophrenia-spectrum disorders who are receiving antipsychotic medications in a geographically defined population in London, UK.
Method
Using information from South London and Maudsley NHS Foundation Trust (SLAM) clinical records, via the Clinical Record Interactive Search system, we identified 6309 individuals who had an ICD-10 diagnosis of schizophrenia-spectrum disorders and were taking antipsychotics at the time of the COVID-19 pandemic onset in the UK. People who were on clozapine treatment were compared with those on any other antipsychotic treatment for risk of contracting COVID-19 between 1 March and 18 May 2020. We tested associations between clozapine treatment and COVID-19 infection, adjusting for gender, age, ethnicity, body mass index (BMI), smoking status and SLAM service use.
Results
Of 6309 participants, 102 tested positive for COVID-19. Individuals who were on clozapine had increased risk of COVID-19 infection compared with those who were on other antipsychotic medication (unadjusted hazard ratio HR = 2 .62, 95% CI 1.73–3.96), which was attenuated after adjusting for potential confounders, including clinical contact (adjusted HR = 1.76, 95% CI 1.14–2.72).
Conclusions
These findings provide support for the hypothesis that clozapine treatment is associated with an increased risk of COVID-19 infection. Further research will be needed in other samples to confirm this association. Potential clinical implications are discussed.
Article activity feed
-
-
SciScore for 10.1101/2020.06.17.20133595: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: CRIS was approved as an anonymised data resource for secondary analysis by Oxfordshire Research Ethics Committee C (reference 18/SC/0372). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Statistical analysis: The data were analysed using STATA for Windows version 15.1. STATAsuggested: (Stata, RRID:SCR_012763)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following …SciScore for 10.1101/2020.06.17.20133595: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: CRIS was approved as an anonymised data resource for secondary analysis by Oxfordshire Research Ethics Committee C (reference 18/SC/0372). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Statistical analysis: The data were analysed using STATA for Windows version 15.1. STATAsuggested: (Stata, RRID:SCR_012763)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Limitations: We controlled for a number of potential confounders; however, there may still be residual confounding. There is a very large effect of inpatient status on the risk of COVID-19 infection. This is likely to arise partly from a higher risk of exposure to COVID-19 in hospital settings, and largely from the policy that inpatients showing any symptoms of COVID-19 were tested, while testing in the community was less comprehensive. Controlling for inpatient status on March 1, 2020, has not annulled the significant association between clozapine and COVID-19. However, we cannot rule out the possibility that clozapine-treated patients could be more likely to be tested for COVID-19, even after accounting for the differences in patient contact and inpatient status between the groups before March 1, 2020. During the study period, the Trust enacted a policy of attempting to discharge patients back into the community where possible, to free up inpatient capacity. We are making an assumption that the proportion of patients discharged did not differ between the clozapine treated group and the non-clozapine-treated group, and that the amount of care and monitoring before versus during the pandemic, remained proportional between groups. The most recent BMI of some patients in the study were from almost 15 years ago. While this is likely to give some indication of the BMI of the patients, it is important to note that BMI is more likely to have been recently measured in clozapine-trea...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
